Please use this identifier to cite or link to this item:
|Title:||Sugammadex.||Austin Authors:||Karalapillai, Dharshi ;Kaufman, Melissa;Weinberg, Laurence||Affiliation:||Austin Health, Heidelberg, Victoria, Australia, Australia||Issue Date:||1-Mar-2013||Publication information:||Critical Care and Resuscitation; 15(1): 57-62||Abstract:||Sugammadex is the first selective antagonist to reverse neuromuscular blockade induced by rocuronium and vecuronium. The mechanism by which sugammadex works is superior to current neuromuscular block reversal strategies in terms of speed, efficacy and side effects. There is little contemporary guidance on the use of sugammadex in intensive care medicine. This review covers the key pharmacological features, clinical uses and cost- effectiveness in the context of intensive care practice.||Gov't Doc #:||23432503||URI:||http://ahro.austin.org.au/austinjspui/handle/1/11682||URL:||https://pubmed.ncbi.nlm.nih.gov/23432503||Type:||Journal Article||Subjects:||Humans
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 7, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.